In this video, Yael Cohen, MD, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, shares some key findings from a real-world study evaluating the safety and efficacy of belantamab mafodotin in patients with relapsed/refractory (R/R) myeloma. Dr Cohen highlights the overall response rate (ORR) and progression-free survival (PFS) observed, and the value of this real-world data. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.